Stonnington Group, LLC Apellis Pharmaceuticals, Inc. Transaction History
Stonnington Group, LLC
- $381 Million
- Q1 2023
A detailed history of Stonnington Group, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Stonnington Group, LLC holds 9,400 shares of APLS stock, worth $229,078. This represents 0.16% of its overall portfolio holdings.
Number of Shares
9,400Holding current value
$229,078% of portfolio
0.16%Shares
6 transactions
Others Institutions Holding APLS
# of Institutions
285Shares Held
124MCall Options Held
921KPut Options Held
761K-
Wellington Management Group LLP Boston, MA12.3MShares$300 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$298 Million4.32% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$290 Million20.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$247 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$235 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.68B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...